Trends and Patterns in Gastrointestinal Cancer Burden in Asia, 1990–2023: Evidence from the Global Burden of Disease Study 2023
- 1Clinical Trials Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China
- 2Department of Epidemiology, School of Public Health, Zhengzhou University, Zhengzhou 450001, China
- 3Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Abstract
Background: Gastrointestinal cancers are among the leading causes of cancer incidence and mortality worldwide and represent a major contributor to the cancer burden in Asia. This study aims to assess the burden of six major gastrointestinal cancers in Asia from 1990 to 2023. Methods: Based on the Global Burden of Disease 2023 data, we analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of six major gastrointestinal cancers—esophageal cancer (EC), stomach cancer (SC), colon and rectum cancer (CRC), liver cancer (LC), pancreatic cancer (PC), and gallbladder and biliary tract cancer (GBTC)—from 1990 to 2023. Results: In 2023, Asia reported about 3.23 million new gastrointestinal cancer cases and 2.26 million deaths, resulting in 55.10 million DALYs. EC had the highest burden in East Asia [age-standardized incidence rate (ASIR): 11.41 per 100,000; age-standardized death rate (ASDR): 10.88 per 100,000; age-standardized DALY rate (ASDALYR): 244.41 per 100,000], while CRC, PC, and GBTC had a high burden in the high-income Asia-Pacific region. From 1990 to 2023, EC, LC, and GBTC declined in most regions, whereas PC increased except in East Asia. The burden was generally higher in males; however, in South Asia, females had higher ASIR (3.35 per 100,000), ASDR (3.44 per 100,000), and ASDALYR (82.94 per 100,000) for GBTC than males. Conclusions: The burden of gastrointestinal cancer in Asia is heavy and unevenly distributed; in the future, more targeted regional prevention and control strategies should be implemented based on socioeconomic levels and the characteristics of the disease spectrum.
Related
- Trends and disparities in upper gastrointestinal cancer among patients with metabolic comorbidities: a retrospective CDC-WONDER analysis (1999–2020)
- Extracorporeal photopheresis for cancer immunotherapy-related gastrointestinal toxicity: emerging clinical evidence.
- Evolving Trends in Early-Onset and Young Adult Gastrointestinal Cancer: Philadelphia in a National Context
- Trends and burden of occupational noise-induced hearing loss in Türkiye: evidence from the national occupational disease registry
- Occupational asbestos exposure and lung cancer: contemporary research trends, exploratory genetic evidence, and global burden from 1990 to 2021
BibTeX
@article{guo2026trends,
title = {{Trends and Patterns in Gastrointestinal Cancer Burden in Asia, 1990–2023: Evidence from the Global Burden of Disease Study 2023}},
author = {Lanwei Guo and Chenxin Zhu and Jiani Yuan and Lin Cai and Huamei Luan and Hongda Chen and Yan Zheng and Yanyan Liu},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213535},
url = {https://www.mdpi.com/2072-6694/18/21/3535},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Trends and Patterns in Gastrointestinal Cancer Burden in Asia, 1990–2023: Evidence from the Global Burden of Disease Study 2023
AU - Lanwei Guo
AU - Chenxin Zhu
AU - Jiani Yuan
AU - Lin Cai
AU - Huamei Luan
AU - Hongda Chen
AU - Yan Zheng
AU - Yanyan Liu
PY - 2026
DA - 2026/11/03
JO - Cancers
DO - 10.3390/cancers18213535
UR - https://www.mdpi.com/2072-6694/18/21/3535
AB - Background: Gastrointestinal cancers are among the leading causes of cancer incidence and mortality worldwide and represent a major contributor to the cancer burden in Asia. This study aims to assess the burden of six major gastrointestinal cancers in Asia from 1990 to 2023. Methods: Based on the Global Burden of Disease 2023 data, we analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of six major gastrointestinal cancers—esophageal cancer (EC), stomach cancer (SC), colon and rectum cancer (CRC), liver cancer (LC), pancreatic cancer (PC), and gallbladder and biliary tract cancer (GBTC)—from 1990 to 2023. Results: In 2023, Asia reported about 3.23 million new gastrointestinal cancer cases and 2.26 million deaths, resulting in 55.10 million DALYs. EC had the highest burden in East Asia [age-standardized incidence rate (ASIR): 11.41 per 100,000; age-standardized death rate (ASDR): 10.88 per 100,000; age-standardized DALY rate (ASDALYR): 244.41 per 100,000], while CRC, PC, and GBTC had a high burden in the high-income Asia-Pacific region. From 1990 to 2023, EC, LC, and GBTC declined in most regions, whereas PC increased except in East Asia. The burden was generally higher in males; however, in South Asia, females had higher ASIR (3.35 per 100,000), ASDR (3.44 per 100,000), and ASDALYR (82.94 per 100,000) for GBTC than males. Conclusions: The burden of gastrointestinal cancer in Asia is heavy and unevenly distributed; in the future, more targeted regional prevention and control strategies should be implemented based on socioeconomic levels and the characteristics of the disease spectrum.
SN - 2072-6694
ER -